Shire plc: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Shire's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights

Strategic insight into the prospects for Shire over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark Shire's performance against key rivals in the prescription pharmaceutical sector* Shire has pulled off the feat of overcoming the loss of its largest product by a long way, Adderall XR. Assess the strategies used to achieve this.* Diversifying away from key historical markets such as ADHD, Shire has built an enviable portfolio of treatments for rare genetic disorders.

[Studien Infos ausblenden]

Executive Summary
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Shire: PharmaVitae forecasts at a glance
Strategic insight
Shire’s ADHD franchise growth
Corporate restructuring: growth via M&A
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
[Missing title]
Q1 2010
Q4 2009
Q3 2009
Latest corporate news
Q2 2010
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Acquisition of Imperial Pharmaceutical Services
Acquisition of Pharmavene
Acquisition of Richwood
Merger with Roberts Pharmaceutical Corporation
Acquisition of Fuisz Technologies’ EU subsidiaries
Acquisition of BioChem Pharma
Acquisition of Atlantic Pharmaceutical
Divestment of OTC products
Divestment of vaccines business
Acquisition of Transkaryotic Therapies
Acquisition of New River Pharmaceuticals
Divestment of non-core products
Acquisition of Jerini
Acquisition of Movetis
Current corporate structure
Specialty Pharmaceuticals
Human Genetic Therapies
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002–08
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
APPENDIX
References
Abbreviations
Exchange rates

[Inhaltsverzeichnis ausblenden]